Evidence map›Paper›PMID 34353897›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2021

Identification of BiP as a CB

Carlos Costas-Insua, Estefanía Moreno, Irene B Maroto, Andrea Ruiz-Calvo, Raquel Bajo-Grañeras, David Martín-Gutiérrez, Rebeca Diez-Alarcia, M Teresa Vilaró, Roser Cortés, Nuria García-Font and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Cannabinoid tolerance relies on CBProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Progress toward a comprehensive brain protein interactome.Biochemical Society transactions · 2025
    Review
  3. Article
  4. Article
  5. The CBEMBO molecular medicine · 2024
    Article
  6. Advice to People with Parkinson's in My Clinic: Cannabis.Journal of Parkinson's disease · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 3 countries.

Carlos Costas-InsuaCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
Estefanía MorenoDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona, University of Barcelona, Barcelona, 08028, Spain.
Irene B MarotoCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
Andrea Ruiz-CalvoCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
Raquel Bajo-GrañerasCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
David Martín-GutiérrezDepartment of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
Rebeca Diez-AlarciaDepartment of Pharmacology, University of the Basque Country/Euskal Herriko Unibertsitatea, Leioa, 48940, Spain.
M Teresa VilaróCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
Roser CortésCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
Nuria García-FontDepartment of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
Ricardo MartínDepartment of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
Marc EspinaCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.ORCID 0000-0002-4043-0457
Joaquín BottaCentre for Endocrinology, William Harvey Research Institute - Barts, and London School of Medicine and Dentistry, Queen Mary University of London, EC1M 6BQ, London, United Kingdom.
Silvia GinésCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
Peter J McCormickCentre for Endocrinology, William Harvey Research Institute - Barts, and London School of Medicine and Dentistry, Queen Mary University of London, EC1M 6BQ, London, United Kingdom.
José Sánchez-PrietoDepartment of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
Ismael Galve-RoperhCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.ORCID 0000-0003-3501-2434
Guadalupe MengodCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
Leyre UrigüenDepartment of Pharmacology, University of the Basque Country/Euskal Herriko Unibertsitatea, Leioa, 48940, Spain.
Giovanni MarsicanoInstitut National de la Santé et de la Recherche Médicale University of Bordeaux, NeuroCentre Magendie, Physiopathologie de la Plasticité Neuronale, Bordeaux, 33077, France.
Luigi BellocchioInstitut National de la Santé et de la Recherche Médicale University of Bordeaux, NeuroCentre Magendie, Physiopathologie de la Plasticité Neuronale, Bordeaux, 33077, France.ORCID 0000-0001-7774-3935
Enric I CanelaCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.ORCID 0000-0003-4992-7440
Vicent CasadóDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona, University of Barcelona, Barcelona, 08028, Spain.
Ignacio Rodríguez-CrespoCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain mguzman@quim.ucm.es jirodrig@quim.ucm.es.
Manuel GuzmánCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain mguzman@quim.ucm.es jirodrig@quim.ucm.es.
Universidad Complutense de Madrid · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESConsejo Superior de Investigaciones Científicas · ESInstitute for Research in Biomedicine · ESQueen Mary University of London · GBUniversité de Bordeaux · FRUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cannabinoids, the bioactive constituents of cannabis, exert a wide array of effects on the brain by engaging Type 1 cannabinoid receptor (CB

Indexed as

AnimalsBrainCannabinoidsEndoplasmic Reticulum Chaperone BiPGABAergic NeuronsHeat-Shock ProteinsHEK293 CellsHumansMiceMice, KnockoutReceptor, Cannabinoid, CB1Signal TransductionCannabinoidsEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsReceptor, Cannabinoid, CB1BiPcannabinoidcell signalingG-protein-coupled receptorneurotransmissionprotein–protein interaction

Identifiers

PMID34353897
PMCPMC8460140
OpenAlexW3187691447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.